Clinical outcome of osteosarcoma and its correlation with programmed death-ligand 1 and T cell activation markers
Open Access
- 1 April 2019
- journal article
- research article
- Published by Taylor & Francis in OncoTargets and Therapy
- Vol. ume 12, 2513-2518
Abstract
Purpose: Although both anti-PD-1 antibody and treatments using anti-PD-L1 antibody are currently in clinical use, their therapeutic effects vary according to cancer type. One of the factors accounting for this variability is the expression level of the immune checkpoint molecule that differs between cancer types; thus, it is important to clarify the relationship between clinical outcomes and immune checkpoint molecules for all types of human cancer. The purpose of this study is to evaluate the clinical outcome of osteosarcoma in relation to PD-L1, PRF, GZMB, and IFNγ expression. Methods: Using 19 clinical specimens of osteosarcoma, we examined the expression of PD-L1, PRF, GZMB, and IFNγ in relation to their clinical outcomes. Results: PD-L1 expression correlated with early metastatic formation in clinical specimens of osteosarcoma, and the group with highly expressed functional markers for T cells such as PRF and GZMB resulted in a long overall survival time. Conclusion: This is the first study to elucidate the clinical outcomes of osteosarcoma in relation to PD-L1, PRF, GZMB, and IFNγ expression. This study provides valuable information regarding the clinical indication and prediction of effect for anti-PD-1 antibody in osteosarcoma.Keywords
This publication has 30 references indexed in Scilit:
- Pediatric osteosarcoma: An updated reviewIndian Journal of Medical and Paediatric Oncology, 2017
- Review of Osteosarcoma and Current ManagementRheumatology and Therapy, 2016
- Osteosarcoma: Current Treatment and a Collaborative Pathway to SuccessJournal of Clinical Oncology, 2015
- Methotrexate, Doxorubicin, and Cisplatin (MAP) Plus Maintenance Pegylated Interferon Alfa-2b Versus MAP Alone in Patients With Resectable High-Grade Osteosarcoma and Good Histologic Response to Preoperative MAP: First Results of the EURAMOS-1 Good Response Randomized Controlled TrialJournal of Clinical Oncology, 2015
- The blockade of immune checkpoints in cancer immunotherapyNature Reviews Cancer, 2012
- Immunotherapy earns its spot in the ranks of cancer therapyJournal of Experimental Medicine, 2012
- Osteosarcoma: Review of the Past, Impact on the Future. The American Experience2009
- Current Status and Perspectives Regarding the Treatment of Osteosarcoma: ChemotherapyReviews on Recent Clinical Trials, 2008
- Prognostic Factors in High-Grade Osteosarcoma of the Extremities or Trunk: An Analysis of 1,702 Patients Treated on Neoadjuvant Cooperative Osteosarcoma Study Group ProtocolsJournal of Clinical Oncology, 2002
- Development of Lupus-like Autoimmune Diseases by Disruption of the PD-1 Gene Encoding an ITIM Motif-Carrying ImmunoreceptorImmunity, 1999